CN Mobile Logo

Search form


Junovan Fails to Win ODAC Nod for Osteosarcoma Treatment

Junovan Fails to Win ODAC Nod for Osteosarcoma Treatment

SILVER SPRING, Maryland—The Oncologic Drugs Advisory Committee (ODAC) voted 12-to-2 not to recommend that FDA approve Junovan (mifamurtide, IDM Pharma) for treating newly diagnosed, resectable high-grade osteosarcomas in combination with chemotherapy following surgical resection.

Junovan is a liposomal formulation of muramyl tripeptide phosphatidylethanolamine (MPT-PE), which induces the infiltration of inflammatory macrophages into lung metastases. IDM Pharma presented data from a phase III NCI-sponsored cooperative group study of 678 nonmetastatic osteosarcoma patients with resectable disease (age range,1.4 to 30.6 years). The study, a factorial design, used two chemotherapy regimens—one standard and one experimental—each with or without Junovan.

The trial showed no statistical advantage for Junovan in disease-free survival, the primary endpoint, although the trend favored the drug. An analysis of overall survival, which was not prespecified in the protocol, showed a 77% 6-year survival probability for Junovan-treated patients vs 66% for those who did not receive the drug (P = .0183). "This robust survival benefit came without cost in safety," said Paul Meyers, MD, of Memorial Sloan-Kettering Cancer Center, who presented the trial data for IDM Pharma.

FDA reviewers said the single study did not provide substantial evidence of effectiveness: The primary endpoint did not reach significance, and the overall survival analysis was not part of the study plan. "Follow-up data have not been rigorously collected and are incomplete, with insufficient follow-up for a significant proportion of patients," said FDA statistical reviewer Laura Lu, PhD.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.